Merus NV stock (NL0011375928): biotech share jumps after solid Q1 data and outlook

Merus NV shares have moved after the Dutch-US biotech group reported first-quarter 2026 results and updated its pipeline, including the petosemtamab program in head and neck cancer. Investors focus on cash runway and upcoming clinical catalysts.

Merus NV has attracted investor attention after the biotech company reported its first-quarter 2026 results and provided an update on its bispecific antibody pipeline, including the petosemtamab program in head and neck cancer, according to a company press release dated 05/08/2026 and subsequent market coverage on 05/09/2026 (Merus investor update as of 05/08/2026, Nasdaq data as of 05/09/2026).

As of: 17.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Merus NV
• Sector/industry: Biotechnology, oncology
• Headquarters/country: Utrecht, Netherlands
• Core markets: Europe and United States, focus on oncology
• Key revenue drivers: Collaboration milestones and license revenues, early-stage product candidates
• Home exchange/listing venue: Nasdaq (ticker: MRUS)
• Trading currency: USD

Merus NV: core business model

Merus NV is a clinical-stage biotech company developing bispecific antibody therapeutics for cancer, with operations in the Netherlands and the United States. The company’s proprietary Biclonics platform is designed to generate full-length human bispecific antibodies that can bind two different targets, a concept that aims to improve anti-tumor activity compared to conventional monoclonal antibodies, as outlined in the company’s description in its annual report for 2025 published on 03/15/2026 (Merus annual report as of 03/15/2026).

The business model centers on advancing an internal pipeline of oncology candidates while entering partnerships with larger pharmaceutical companies to share development risk and obtain upfront payments, milestones, and royalties. Merus emphasizes solid tumors and hematologic malignancies, targeting pathways that are clinically validated or strongly supported by preclinical data, according to management commentary in the first-quarter 2026 earnings materials released on 05/08/2026 (Merus Q1 2026 results as of 05/08/2026).

Unlike large diversified pharmaceutical companies, Merus is highly concentrated on a narrow set of experimental assets that are still in clinical development. The company generates modest revenue primarily from collaboration agreements and has not yet commercialized a product, so it currently depends on external funding and cash reserves to finance multi-year clinical trials. This early-stage structure is typical for Nasdaq-listed biotech companies that target oncology indications with high unmet medical need.

Main revenue and product drivers for Merus NV

The most advanced program at Merus is petosemtamab, an EGFR x LGR5 bispecific antibody being evaluated in head and neck squamous cell carcinoma and colorectal cancer. In its first-quarter 2026 update published on 05/08/2026, the company highlighted ongoing enrollment in studies designed to support potential registrational pathways in head and neck cancer and shared additional safety and efficacy data that management described as encouraging, while emphasizing that longer follow-up and larger datasets will be required (Merus investor update as of 05/08/2026).

Beyond petosemtamab, Merus is advancing a portfolio of bispecific antibody candidates such as zenocutuzumab (MCLA-128), which targets NRG1 fusion-positive solid tumors. The company’s approach has attracted collaboration partners who provide funding through upfront payments and research support. These partnerships contribute to revenue and can generate milestones when specific development objectives are achieved, as described in the annual report for 2025 released on 03/15/2026 (Merus annual report as of 03/15/2026).

Financially, Merus reported first-quarter 2026 collaboration revenue in the low double-digit million USD range and a net loss, reflecting ongoing R&D investments into clinical trials and platform development, according to the Q1 2026 press release dated 05/08/2026 (Merus Q1 2026 results as of 05/08/2026). Management also reiterated its cash runway guidance, stating that existing cash, cash equivalents, and marketable securities are expected to fund operations into 2028, which is intended to provide a financial buffer for late-stage studies.

Share price performance around the Q1 update reflected investor reactions to both clinical details and cash guidance. On 05/09/2026, the stock traded in the mid-30 USD range on Nasdaq, corresponding to a move of several percentage points compared with levels prior to the earnings release, according to intraday data from Nasdaq on that date (Nasdaq data as of 05/09/2026). For US investors, this reinforced the sensitivity of Merus NV shares to incremental news on clinical progress and financing.

Conclusion

Merus NV remains a typical clinical-stage oncology biotech with a focused pipeline of bispecific antibodies, led by petosemtamab and supported by collaboration-derived revenue. The recent first-quarter 2026 update, published on 05/08/2026, highlighted steady progress in key programs and reaffirmed a cash runway into 2028, which contributed to noticeable share price movements on Nasdaq in the following trading sessions, according to market data as of 05/09/2026 (Merus Q1 2026 results as of 05/08/2026, Nasdaq data as of 05/09/2026). For US investors following the biotech sector, the stock offers exposure to targeted oncology research, but its outlook continues to depend on clinical readouts, regulatory paths, and the company’s ability to maintain sufficient funding for late-stage trials.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.